Reports: Brian Rolapp leaving NFL to become PGA Tour's CEO
June 13 - NFL executive vice president Brian Rolapp is headed for a new role as the CEO for the PGA Tour, multiple media outlets reported on Thursday.
According to reports, Rolapp decided to depart his role after working 22 years with NFL. The hiring at the PGA Tour has not been confirmed, but NFL commissioner Roger Goodell reportedly messaged team execs Thursday informing them of Rolapp's decision.
Rolapp will take charge of PGA Tour Enterprises, the circuit's newly created for-profit outfit, The Athletic reported.
The PGA Tour has been seeking a CEO to work alongside commissioner Jay Monahan since December. A few notable names have been linked with the position, including NASCAR commissioner Steve Phelps.
Rolapp stands as a natural fit, as he has been NFL's lead media and business officer during a period of exponential growth by the league. He is considered a potential successor for Goodell, and a new role as a CEO at a different pro sports endeavor likely wouldn't change that.
Rolapp has been in his current role overseeing advertising, sponsorships and media contracts since 2017. Before then, he was the NFL COO and senior VP of media strategy and digital media. He also was the CEO of NFL Network and executive VP of NFL Media.
The PGA Tour has a committee that has been in search of the next CEO. It includes Monahan, PGA Tour player directors Tiger Woods and Adam Scott and Atlanta Falcons owner Arthur Blank, among others.
Monahan, whom Rolapp would report to, replaced Tim Finchem as commissioner of the PGA Tour in January 2017, becoming the fourth person to serve in that role.
--Field Level Media
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
29 minutes ago
- Reuters
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
June 13 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on Friday. The 12-week result was published in an abstract ahead of the American Diabetes Association conference in Chicago, the brokerage said. Cantor analyst Prakhar Agrawal said the data on eloralintide looked strong in terms of weight loss and safety, adding that expectations for the drug had been low. The drug belongs to a class of medicines that mimic the pancreatic hormone amylin, which is co-secreted with insulin. Amylin slows digestion and suppresses hunger. Mid-stage trials are ongoing, both as a standalone treatment and in combination with Lilly's blockbuster GLP-1 drug, tirzepatide, sold as Zepbound. The first wave of obesity drugs focused mainly on the gut hormone GLP-1, but drugmakers are now looking for medicines that target other hormones or help preserve muscle mass during fat-loss for their next generation of drugs. We think the data today is a sign that the real successor to tirzepatide is the tirzepatide-eloralintide combo, said Jefferies analyst Akash Tewari. In March, Roche (ROG.S), opens new tab acquired the rights to Zealand Pharma's long-acting amylin analogue, petrelintide, in a collaboration valued at up to $5.3 billion. Similarly, Novo Nordisk ( opens new tab is banking on a dual mode of action involving amylin for its next generation of drugs, with experimental compounds called amycretin and CagriSema, while AstraZeneca (AZN.L), opens new tab has an amylin-based obesity drug in early trials. Lilly's eloralintide weight-loss data is tracking better than Roche and Zealand's petrelintide, said Agrawal, adding the data is meaningfully better than Novo's monotherapy. Data at 12 weeks is also competitive compared to other drug classes such as GLP-1, Agrawal also said. Eli Lilly did not immediately respond to a Reuters request for comment.
Reuters
an hour ago
- Reuters
Trump urged EchoStar, FCC chair to cut a deal on spectrum -Bloomberg
WASHINGTON, June 13 (Reuters) - President Donald Trump urged EchoStar Corp (SATS.O), opens new tab Chairman Charlie Ergen and Federal Communications Commission Chair Brendan Carr to reach a deal over the fate of the company's wireless spectrum licenses, Bloomberg reported on Friday. EchoStar shares were up 52% in after-hours trading Friday on the report. On Thursday, Trump met with Ergen and he telephoned Carr, who came to the White House to join the meeting, Bloomberg reported. The White House and EchoStar declined to comment. The FCC did not immediately respond to a request from Reuters for comment on Friday. EchoStar has been trying to shield its cache of wireless spectrum licenses from the threat of revocation by the FCC. U.S. satellite TV provider DirecTV terminated its agreement to acquire EchoStar's satellite television business last year, which includes rival Dish TV, over a failed debt-exchange offer. In May, the FCC told EchoStar it was investigating the company's compliance obligations to provide 5G service in the U.S., questioning EchoStar's buildout extension and mobile-satellite service. EchoStar said the FCC disclosure was "harming EchoStar's ongoing deployment and threaten its viability as a wireless provider as well as endanger the video and broadband satellite services upon which millions of consumers rely." The company added "the possibility of reversing prior grants of authority related to spectrum for which EchoStar paid billions and in which it invested billions more, in contravention of long-standing commission precedent." EchoStar has previously disclosed that it missed roughly $500 million in interest payments, citing uncertainty around the ongoing FCC review.
Daily Mail
an hour ago
- Daily Mail
BREAKING NEWS Moment furious Rory McIlroy launches his club in anger as US Open woes continue
Rory McIlroy 's frustrations boiled over at the US Open on Friday as his worrying run of post-Masters form continued. While fighting to get back on the right side of the cut line after a four-over-par 74 on Thursday, the Northern Irishman endured similar difficulties in his second round on a testing Oakmont surface. And after miscuing his second shot on the venue's monster par-five 12th, he couldn't resist launching his club in fury as he dropped to +8 - leaving him just one shot behind the projected cut line. McIlroy has struggled since ending his major drought and completing a career Grand Slam at the Masters in April, having finished 14 shots behind PGA Championship winner Scottie Scheffler the following month and missed the cut at the Canadian Open last week. More to follow.
